Brisk M&A in domestic pharmaceutical industry

Published: 2003-07-18 06:59:00

Updated: 2003-07-18 06:59:00

Stimulated by the current consensus that domestic pharmaceutical industry is one of the high value-added industries and growing concern on the biotechnology field, the M&A fever are pronouncing among pharmaceuticals firms and financial investment companies.

KT&G is seeking to advance into the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK